ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential treatment for obesity. The results were presented in a poster ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...

We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...

State of New Jersey Common Pension Fund D raised its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...

Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...

In this article, we are going to take a look at where Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stands against other most oversold healthcare stocks to buy now. Healthcare costs and spending ...

Stock analysts at B. Riley raised their FY2025 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued ...

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), with a ...